Reading time is <1 mins


Prof. Dr. “Unlike hydroxychloroquine, it does not cause significant side effects in terms of safety,” Mehmet Ceyhan said of the drug Favipiravir used to treat Covid-19 patients.

The Department of Health has updated its covid-19 treatment guidelines. The drug with the active ingredient hydroxychloroquine, which is used to treat the disease and has been discussed for some time due to its side effects, has been removed from the guide.

Accordingly, corona virus patients treated both in hospital and at home will not be given drugs with the active ingredient hydroxychloroquine.

Turkey Head Of The Department Of Pediatric Infectious Diseases Prof. Dr. made a statement on his Twitter account regarding the drug Favipiravir, which is used in the treatment of patients suffering from coronavirus.

Prof. Dr. “Favipiravir is reliable and effective in the treatment of Covid-19,” said in a statement with the title,” Favipiravir has no effect on a large number of metaanalysis. Claims that it is effective appear in press releases and Chinese publications rather than in medical journals,” he said.


Turkish Prof. Dr in Ankara Turkey, explains “Unlike hydroxychloroquine, it does not cause significant side effects from a safety point of view, so it is widely used,” said of difference between Favipyravirin and hydroxychloroquine. We children have never used hydroxychloroquine since the beginning, and we do not use Favipiraviri except in rare cases. Antibodies such as Banlanivimab, which may be more effective in treatment, are very expensive and can only be used early for those at risk of severe disease. Patients who have used Favipiravir do not need to worry, there is no data that significant side effects develop over a long period of time. As a result, still the most effective treatment is support therapy, rather than drug therapy; liquid, oxygen, observation when necessary,” he said.


Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.


Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.


Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.


Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me
Latest posts by Medically Reviewed by Professor Doctor Alper Demirbaş (see all)